Vaccines
9 November 2018
Gradalis® Presents Initial Data from Phase II U.S. Trial for Ewing’s sarcoma at the Annual Meeting of the Children’s Oncology Group8 November 2018
Neovacs announces in vivo Proof of Concept success for its IL-4 / IL-13 Kinoid a new Therapeutic Vaccine to treat Mite-induced Asthma5 November 2018
Curevo Announces FDA Advancement of IND Application for CRV-101, New Shingles Vaccine Candidate5 November 2018
Imcyse successfully completes patient enrollment in first-in-human Phase 1b study in type 1 diabetes31 October 2018
Daiichi Sankyo Announces Discontinuation of Intradermal Seasonal Influenza Vaccine Development in Japan25 October 2018
Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses25 October 2018
Johnson & Johnson Announces Promising, Early-Stage Results for Tetravalent Mosaic-based HIV Preventive Vaccine Regimen23 October 2018
Trial to provide first-in-human data for CureVac’s novel mRNA-based intramuscular rabies vaccine23 October 2018
Inovio presents progression free survival & PSA doubling time improvements in prostate cancer patients treated with INO-515022 October 2018
DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration19 October 2018
Sanofi receives positive CHMP opinion for dengue vaccine16 October 2018
Targovax Reports Encouraging Disease-free Survival (DFS) Data From Tg01 Trial in Resected Pancreatic Cancer16 October 2018
Inovio’s Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune Responses in Preclinical Studies10 October 2018
IAVI Announces Clinical Trial of Next-Generation HIV Vaccine Candidate Designed to Induce Antibodies to Block HIV Infection5 October 2018
New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity5 October 2018
FluGen Presents First-in-Human Phase 1a Safety and Immunogenicity Data with Novel M2SR Influenza Vaccine at ID Week27 September 2018
ImmusanT Announces First Patient Dosed in Phase 2 Trial of Therapeutic Vaccine for Celiac Disease27 September 2018
OncBioMune Initiates Phase 2 Clinical Trial of Novel Vaccine as Front-Line Treatment for Prostate Cancer27 September 2018
GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study21 September 2018
AIVITA Biomedical Announces Treatment of First Patient in Phase 2 Ovarian Cancer TrialNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports